BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 28870917)

  • 1. The Association Between HSP90/topoisomerase I Immunophenotype and the Clinical Features of Colorectal Cancers in Respect to
    Bar JK; Lis-Nawara A; Grelewski P; Noga L; Grzebieniak Z; Jeleń M
    Anticancer Res; 2017 Sep; 37(9):4953-4960. PubMed ID: 28870917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.
    Abubaker J; Bavi P; Al-Haqawi W; Sultana M; Al-Harbi S; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
    J Pathol; 2009 Dec; 219(4):435-45. PubMed ID: 19824059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior.
    Jang S; Hong M; Shin MK; Kim BC; Shin HS; Yu E; Hong SM; Kim J; Chun SM; Kim TI; Choi KC; Ko YW; Kim JW
    Hum Pathol; 2017 Jul; 65():21-30. PubMed ID: 28188750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancer.
    Cercek A; Shia J; Gollub M; Chou JF; Capanu M; Raasch P; Reidy-Lagunes D; Proia DA; Vakiani E; Solit DB; Saltz LB
    Clin Colorectal Cancer; 2014 Dec; 13(4):207-12. PubMed ID: 25444464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P21WAF1/CIP1 expression in colorectal carcinomas is related to Kras mutations and prognosis.
    Mitomi H; Ohkura Y; Fukui N; Kanazawa H; Kishimoto I; Nakamura T; Yokoyama K; Sada M; Kobayashi K; Tanabe S; Saigenji K
    Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):883-9. PubMed ID: 17873613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAS status in Korean patients with stage III and IV colorectal cancer.
    Lee WS; Lee JN; Baek JH; Park YH
    Clin Transl Oncol; 2015 Sep; 17(9):751-6. PubMed ID: 25997687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR, BRAF and KRAS status in patients undergoing pulmonary metastasectomy from primary colorectal carcinoma: a prospective follow-up study.
    Schweiger T; Hegedüs B; Nikolowsky C; Hegedüs Z; Szirtes I; Mair R; Birner P; Döme B; Lang G; Klepetko W; Ankersmit HJ; Hoetzenecker K
    Ann Surg Oncol; 2014 Mar; 21(3):946-54. PubMed ID: 24281417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases.
    Boonsong A; Curran S; McKay JA; Cassidy J; Murray GI; McLeod HL
    Hum Pathol; 2002 Nov; 33(11):1114-9. PubMed ID: 12454816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic relevance of autophagy-related markers LC3, p62/sequestosome 1, Beclin-1 and ULK1 in colorectal cancer patients with respect to KRAS mutational status.
    Schmitz KJ; Ademi C; Bertram S; Schmid KW; Baba HA
    World J Surg Oncol; 2016 Jul; 14(1):189. PubMed ID: 27444698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study.
    Chen KH; Shao YY; Chen HM; Lin YL; Lin ZZ; Lai MS; Cheng AL; Yeh KH
    BMC Cancer; 2016 May; 16():327. PubMed ID: 27221731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of FIH-1 and SOCS3 expression in KRAS mutant and wild-type patients with colorectal cancer.
    Vakil L; Najafipour R; Rakhshani N; Zamani F; Morakabati A; Javadi A
    Tumour Biol; 2016 Jul; 37(7):8841-8. PubMed ID: 26749281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRAS and aneusomy of chromosomes 4, 10 and 12 in colorectal carcinomas.
    Beyer K; Altendorf-Hofmann A; Chen Y; Bickel K; Petersen I
    Pathol Res Pract; 2015 Sep; 211(9):646-51. PubMed ID: 26122820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor and Kras gene expression: reliability of mutational analysis on cytological samples.
    Bozzetti C; Negri FV; Azzoni C; Naldi N; Nizzoli R; Bortesi B; Zobbi V; Bottarelli L; Tiseo M; Silini EM; Ardizzoni A
    Diagn Cytopathol; 2013 Jul; 41(7):595-8. PubMed ID: 22833420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
    Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages.
    Li W; Qiu T; Zhi W; Shi S; Zou S; Ling Y; Shan L; Ying J; Lu N
    BMC Cancer; 2015 May; 15():340. PubMed ID: 25929517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct Clinicopathological Patterns of Mismatch Repair Status in Colorectal Cancer Stratified by KRAS Mutations.
    Li W; Zhi W; Zou S; Qiu T; Ling Y; Shan L; Shi S; Ying J
    PLoS One; 2015; 10(6):e0128202. PubMed ID: 26042813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
    Zhang X; Wang Y; Gao N; Wang J
    Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HSP27 expression in primary colorectal cancers is dependent on mutation of KRAS and PI3K/AKT activation status and is independent of TP53.
    Ghosh A; Lai C; McDonald S; Suraweera N; Sengupta N; Propper D; Dorudi S; Silver A
    Exp Mol Pathol; 2013 Feb; 94(1):103-8. PubMed ID: 22982087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Detection of KRAS gene mutation and its clinical significance in colorectal adenocarcinoma].
    Xu C; Liu YL; Huang J; He DM; Hou YY; Ji Y; Hou J; Lu SH; Xu JF; Hu Q; Shi Y; Zhao LJ; Tan YS
    Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):667-70. PubMed ID: 23302307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases.
    Fujiyoshi K; Yamamoto G; Takahashi A; Arai Y; Yamada M; Kakuta M; Yamaguchi K; Akagi Y; Nishimura Y; Sakamoto H; Akagi K
    Oncol Rep; 2017 Feb; 37(2):785-792. PubMed ID: 28000889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.